Nexvet

Nexvet Biopharma was a clinical-stage veterinary biopharmaceutical company focused on developing species-specific biologic therapies for companion animals, including dogs and cats. The company utilized its proprietary PETization™ platform to create monoclonal antibodies recognized as native by the target animal's immune system. Nexvet's operations included drug discovery in Australia, clinical development in the United States and Europe, and biomanufacturing in Ireland. In April 2017, Nexvet was acquired by Zoetis, a global animal health company.